Xencor, Inc
Xencor is an innovative biotechnology company that specializes in engineering antibody therapeutics using its proprietary XmAb platform. The company focuses on developing drugs for cancer, autoimmune disorders, and infectious diseases, with a broad pipeline of clinical and preclinical programs. Xencor's technology enables the creation of highly effective, stable, and long-acting antibody drugs, including bispecific antibodies, with a plug-and-play Fc domain platform. The company collaborates with leading biopharmaceutical partners and has a strong intellectual property portfolio.
Industries
Nr. of Employees
large (251-1000)
Xencor, Inc
Products
ENPP3 × CD3 2+1 bispecific antibody (renal cell carcinoma, Phase 1)
A 2+1 bispecific antibody format targeting ENPP3 and CD3 designed for treatment of renal cell carcinoma; entered Phase 1 clinical testing.
CLDN6 × CD3 2+1 bispecific with half-life extension (ovarian cancer, Phase 1)
A 2+1 bispecific antibody targeting CLDN6 and CD3 with an Fc design that supports extended half-life, in Phase 1 testing for ovarian cancer.
B7-H3 × CD28 2+1 bispecific antibody (oncology, Phase 1)
A tumor-targeted CD28 costimulatory bispecific antibody in a 2+1 format developed for combination with checkpoint inhibitors and T-cell engagers; in Phase 1 testing.
Anti-TL1A antibody with extended half-life (inflammatory bowel disease, Phase 1/2)
An anti-TL1A monoclonal antibody engineered for extended circulating half-life, in Phase 1/2 testing for ulcerative colitis and inflammatory bowel disease.
CD20 × CD3 bispecific antibody (B‑cell malignancies, Phase 1/2)
A CD20×CD3 bispecific antibody developed for B‑cell malignancies, evaluated in early clinical studies including subcutaneous administration assessments.
STEAP1 × CD3 2+1 bispecific antibody (prostate cancer, Phase 3 partner-led)
A partner-developed STEAP1×CD3 2+1 bispecific antibody in late-stage testing for metastatic castration-resistant prostate cancer, based on licensed Fc bispecific platform.
ENPP3 × CD3 2+1 bispecific antibody (renal cell carcinoma, Phase 1)
A 2+1 bispecific antibody format targeting ENPP3 and CD3 designed for treatment of renal cell carcinoma; entered Phase 1 clinical testing.
CLDN6 × CD3 2+1 bispecific with half-life extension (ovarian cancer, Phase 1)
A 2+1 bispecific antibody targeting CLDN6 and CD3 with an Fc design that supports extended half-life, in Phase 1 testing for ovarian cancer.
B7-H3 × CD28 2+1 bispecific antibody (oncology, Phase 1)
A tumor-targeted CD28 costimulatory bispecific antibody in a 2+1 format developed for combination with checkpoint inhibitors and T-cell engagers; in Phase 1 testing.
Anti-TL1A antibody with extended half-life (inflammatory bowel disease, Phase 1/2)
An anti-TL1A monoclonal antibody engineered for extended circulating half-life, in Phase 1/2 testing for ulcerative colitis and inflammatory bowel disease.
CD20 × CD3 bispecific antibody (B‑cell malignancies, Phase 1/2)
A CD20×CD3 bispecific antibody developed for B‑cell malignancies, evaluated in early clinical studies including subcutaneous administration assessments.
STEAP1 × CD3 2+1 bispecific antibody (prostate cancer, Phase 3 partner-led)
A partner-developed STEAP1×CD3 2+1 bispecific antibody in late-stage testing for metastatic castration-resistant prostate cancer, based on licensed Fc bispecific platform.
Services
Licensing of Fc engineering domains
Granting licenses for engineered Fc domains to external partners to incorporate into therapeutic antibody or cytokine candidates; may include limited collaborative R&D support.
Early-phase clinical development support
Design and conduct of Phase 1 and Phase 1/2 clinical studies including dose escalation, safety/tolerability assessments, PK characterization and expansion cohorts.
Analytical and preclinical characterization
In vitro and in vivo pharmacology, receptor-binding and stability assays, and nonclinical safety studies to support candidate selection and IND-enabling packages.
Licensing of Fc engineering domains
Granting licenses for engineered Fc domains to external partners to incorporate into therapeutic antibody or cytokine candidates; may include limited collaborative R&D support.
Early-phase clinical development support
Design and conduct of Phase 1 and Phase 1/2 clinical studies including dose escalation, safety/tolerability assessments, PK characterization and expansion cohorts.
Analytical and preclinical characterization
In vitro and in vivo pharmacology, receptor-binding and stability assays, and nonclinical safety studies to support candidate selection and IND-enabling packages.
Expertise Areas
- Fc-domain engineering for therapeutic antibodies
- Bispecific antibody development (2+1 and heterodimeric formats)
- Early-phase clinical development and dose-finding
- Structure-based protein design
Key Technologies
- Fc domain engineering
- Bispecific antibody formats (2+1)
- Heterodimeric Fc platforms
- FcRn-binding enhancement for half-life extension